Extended Data Fig. 5: Swimmer plots for SoC and TT in exploratory hTMB, MSI, BRAF and HER2 subgroups.
From: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
a) hTMB SOC; b) hTMB TT; c) HER2 alterations SOC; d) HER2 alterations TT; e) MSI-H; F) BRAF alterations. TT: tailored treatment; SOC: standard of care; PD: Progressive disease; NE: Not evaluable; SD: Stable disease; PR: Partial response; CR: Complete response; hTMB: High tumor mutational burden; MSI-H: microsatellite instability high.
